Sysmex Corporation

PINK:SSMXF USA Medical Devices
Market Cap
$12.05 Billion
Market Cap Rank
#1916 Global
#1387 in USA
Share Price
$19.34
Change (1 day)
+1.08%
52-Week Range
$19.13 - $19.34
All Time High
$43.34
About

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. It offers non-clinical blood testing and cell analysis for hematology, such as XN-V series, a software for laboratory animal corresponding to XN series fully automated hematology analyzers; XN-Series, a fully automated flagship hematology analyzers; and Automated hematol… Read more

Sysmex Corporation (SSMXF) - Net Assets

Latest net assets as of December 2025: $501.87 Billion USD

Based on the latest financial reports, Sysmex Corporation (SSMXF) has net assets worth $501.87 Billion USD as of December 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($698.86 Billion) and total liabilities ($196.99 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets $501.87 Billion
% of Total Assets 71.81%
Annual Growth Rate 11.14%
5-Year Change 50.5%
10-Year Change 146.97%
Growth Volatility 4.48

Sysmex Corporation - Net Assets Trend (2005–2025)

This chart illustrates how Sysmex Corporation's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Sysmex Corporation (2005–2025)

The table below shows the annual net assets of Sysmex Corporation from 2005 to 2025.

Year Net Assets Change
2025-03-31 $464.53 Billion +7.31%
2024-03-31 $432.90 Billion +11.47%
2023-03-31 $388.36 Billion +11.26%
2022-03-31 $349.05 Billion +13.08%
2021-03-31 $308.67 Billion +10.89%
2020-03-31 $278.35 Billion +4.96%
2019-03-31 $265.18 Billion +9.83%
2018-03-31 $241.44 Billion +14.84%
2017-03-31 $210.25 Billion +11.78%
2016-03-31 $188.09 Billion +10.94%
2015-03-31 $169.55 Billion +15.93%
2014-03-31 $146.25 Billion +22.74%
2013-03-31 $119.15 Billion +16.24%
2012-03-31 $102.50 Billion +8.78%
2011-03-31 $94.23 Billion +8.14%
2010-03-31 $87.14 Billion +9.12%
2009-03-31 $79.85 Billion +0.93%
2008-03-31 $79.12 Billion +9.28%
2007-03-31 $72.40 Billion +15.56%
2006-03-31 $62.65 Billion +11.57%
2005-03-31 $56.15 Billion --

Equity Component Analysis

This analysis shows how different components contribute to Sysmex Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 1017.4% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (March 2025)

Component Amount Percentage
Retained Earnings $402.82 Billion 86.86%
Common Stock $14.89 Billion 3.21%
Other Comprehensive Income $37.43 Billion 8.07%
Other Components $8.64 Billion 1.86%
Total Equity $463.78 Billion 100.00%

Sysmex Corporation Competitors by Market Cap

The table below lists competitors of Sysmex Corporation ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Sysmex Corporation's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 432,045,000,000 to 463,776,000,000, a change of 31,731,000,000 (7.3%).
  • Net income of 53,669,000,000 contributed positively to equity growth.
  • Dividend payments of 18,081,000,000 reduced retained earnings.
  • Share repurchases of 2,000,000 reduced equity.
  • New share issuances of 248,000,000 increased equity.
  • Other comprehensive income decreased equity by 5,389,000,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income $53.67 Billion +11.57%
Dividends Paid $18.08 Billion -3.9%
Share Repurchases $2.00 Million -0.0%
Share Issuances $248.00 Million +0.05%
Other Comprehensive Income $-5.39 Billion -1.16%
Other Changes $1.29 Billion +0.28%
Total Change $- 7.34%

Book Value vs Market Value Analysis

This analysis compares Sysmex Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.03x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2005-03-31 $268.03 $19.34 x
2006-03-31 $299.21 $19.34 x
2007-03-31 $352.39 $19.34 x
2008-03-31 $385.67 $19.34 x
2009-03-31 $389.35 $19.34 x
2010-03-31 $850.03 $19.34 x
2011-03-31 $457.68 $19.34 x
2012-03-31 $498.17 $19.34 x
2013-03-31 $576.46 $19.34 x
2014-03-31 $234.91 $19.34 x
2015-03-31 $271.16 $19.34 x
2016-03-31 $901.73 $19.34 x
2017-03-31 $1003.54 $19.34 x
2018-03-31 $1152.99 $19.34 x
2019-03-31 $1265.57 $19.34 x
2020-03-31 $1328.37 $19.34 x
2021-03-31 $1470.46 $19.34 x
2022-03-31 $1662.76 $19.34 x
2023-03-31 $617.34 $19.34 x
2024-03-31 $689.68 $19.34 x
2025-03-31 $743.56 $19.34 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Sysmex Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 11.57%
  • The company shows good efficiency in utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 10.55%
  • • Asset Turnover: 0.76x
  • • Equity Multiplier: 1.43x
  • Recent ROE (11.57%) is below the historical average (13.14%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2005 10.35% 7.45% 0.99x 1.40x $196.30 Million
2006 12.01% 8.44% 1.01x 1.42x $1.24 Billion
2007 12.63% 8.92% 1.00x 1.42x $1.87 Billion
2008 11.56% 8.25% 1.02x 1.38x $1.23 Billion
2009 10.05% 7.16% 0.94x 1.49x $36.90 Million
2010 11.22% 8.40% 0.96x 1.39x $1.06 Billion
2011 12.12% 9.15% 0.96x 1.38x $2.00 Billion
2012 11.73% 8.91% 0.95x 1.39x $1.77 Billion
2013 11.89% 9.73% 0.84x 1.45x $2.25 Billion
2014 14.07% 11.15% 0.88x 1.44x $5.95 Billion
2015 15.71% 12.03% 0.89x 1.46x $9.68 Billion
2016 20.88% 15.52% 0.95x 1.42x $20.47 Billion
2017 19.41% 16.26% 0.89x 1.34x $19.70 Billion
2018 16.29% 13.91% 0.88x 1.34x $15.15 Billion
2019 15.59% 14.05% 0.85x 1.31x $14.78 Billion
2020 12.56% 11.55% 0.78x 1.40x $7.11 Billion
2021 10.36% 10.46% 0.71x 1.39x $1.11 Billion
2022 12.66% 12.12% 0.75x 1.39x $9.26 Billion
2023 11.81% 11.15% 0.77x 1.37x $7.02 Billion
2024 11.49% 10.76% 0.75x 1.43x $6.43 Billion
2025 11.57% 10.55% 0.76x 1.43x $7.29 Billion

Industry Comparison

This section compares Sysmex Corporation's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

  • Industry: Medical Devices
  • Average net assets among peers: $694,749,556
  • Average return on equity (ROE) among peers: -25.46%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Sysmex Corporation (SSMXF) $501.87 Billion 10.35% 0.39x $8.29 Billion
Advanced Biomedical Technologies Inc (ABMT) $-4.46 Million 0.00% 0.00x $14.18K
Abbott Laboratories (ABT) $4.82 Billion 39.04% 1.31x $191.37 Billion
Acarix AB (publ) (ACIXF) $1.93 Million -127.02% 0.21x $26.42 Million
Adagio Medical Holdings, Inc Common Stock (ADGM) $-72.62 Million 0.00% 0.00x $4.05 Million
Adm Tronics Unltd (ADMT) $-12.69K 0.00% 0.00x $3.17 Million
Aethlon Medical Inc (AEMD) $-3.07 Million 0.00% 0.00x $2.79 Million
Acutus Medical Inc (AFIB) $126.58 Million -80.56% 0.52x $732.88K
Adapthealth Corp (AHCO) $2.07 Billion 7.56% 1.54x $914.25 Million
Allied Healthcare Products Inc. (AHPIQ) $8.88 Million -33.95% 1.22x $726.24
20/20 Biolabs, Inc. Common Stock (AIDX) $3.39 Million -59.65% 0.38x $9.18 Million